The Tandem t:slim X2 has been approved by the U.S. FDA as an "interoperable" insulin pump. An interoperable pump can be used with different components that make up diabetes therapy systems, allowing patients to tailor their diabetes management to their individual device preferences, which opens up huge future possibilities for closed-loop systems and other management technologies. In 2018, the Dexcom G6 was designated the first interoperable continuous glucose monitor by the FDA.
Read the full press release from the FDA here.
The Future of Tandem
In November, Diatribe wrote a fantastic article about what's on the horizon for Tandem, including the Control-IQ hybrid closed loop, the "interoperable" pump designation, the t:connect mobile app, and the t:sport patch pump with hybrid wear.